Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data expected in 2025. Click for my IMVT update.

Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical ...

Safety and tolerability were observed to be consistent with prior batoclimab studies. Path Forward in MG and CIDP Immunovant plans to initiate potentially registrational studies in both MG and ...

Wednesday, Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic ...

Batoclimab met the primary endpoint in a Phase 3 MG study, showing up to a 5.6-point MG-ADL improvement with 74% mean IgG reduction. Immunovant will not seek approval for batoclimab in MG or CIDP ...

Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP. The Phase 3 study in MG is a randomized ...

patients were randomized into 680mg and 340mg batoclimab only, the firm says. The firm has a Buy rating and $51 price target on Immunovant shares, and says the “more is better” debate has not ...

at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical outcomes - will apply to a wide range of auto-antibody mediated conditions,” said Pete Salzmann, M.D.

Safety and tolerability were observed to be consistent with prior batoclimab studies. Path Forward in MG and CIDP Immunovant plans to initiate potentially registrational studies in both MG and CIDP ...